$NTRA

Chapman Steven Leonard sold $279K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,300 shares of Natera, Inc. (NTRA) at $214.83 ($0.28M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Jun 6, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 6, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure may influence short-term sentiment, but 10b5-1 structure generally limits inference about near-term business outlook.

02

Market read

Traders may monitor whether additional insider sales occur, but this single 10b5-1 sale is unlikely to drive a durable repricing alone.

03

What to watch

The sale size is modest relative to typical large-cap float; without additional context (e.g., total planned volume, prior sales), signal is weak.

Relevance 6/10Novelty 4/10Timing: insider sale disclosed after-hours/next session following the 2026-06-04 trade date

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the CEO/president under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold $279,279 of NTRA shares via an open-market transaction disclosed on Form 4.

Expected impact

Likely limited/short-lived impact; any reaction should fade unless accompanied by other negative company-specific news.

Evidence & confidence

The filing is an insider transaction (not earnings/M&A/regulatory). It explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive value versus discretionary selling.

Market effects

Minimal; this is company-specific insider liquidity rather than a sector catalyst.

None.

None.

Counterpoint

If the market treats 10b5-1 sales as still informative, the stock could see a brief dip as traders front-run potential future selling.

Key entities

  • Natera, Inc.

    Subject of the insider transaction disclosure; CEO/president sold shares on 2026-06-04.

Related articles

$NTRAHighAI 9/10

Natera Stock Jumps After Q2 Beat And Guidance Hike

Natera Inc. (NTRA) shares rose about 20.9% after Q2 results and guidance. Q2 revenue was $752.8M versus $661.2M consensus, with a Q2 loss of $0.47 per share versus $0.49 expected. Full-year 2026 revenue guidance was raised to $2.85B to $2.91B. The Signatera test was submitted to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

NTRA Soars As Natera Beats Q2 And Lifts 2026 Outlook

Natera (NTRA) shares rose about 21% after the company reported Q2 2026 revenue of $752.8M versus ~$661.2M consensus and a $0.47 per-share loss versus a ~$0.49 loss estimate. Natera lifted FY2026 revenue guidance to $2.85B to $2.91B. The article cites gross margin around 65% and notes free cash flow about $18M.

$NTRAHighAI 9/10

NTRA Stock Soars After Earnings Beat And Raised 2026 Outlook

Natera Inc. (NTRA) shares rose after Q2 results and a raised 2026 outlook. According to the company, Q2 revenue was $752.8M vs $661.2M consensus, with a Q2 loss of $0.47 per share vs $0.49 expected. Full-year 2026 revenue guidance was lifted to $2.85B–$2.91B. The company also submitted its Signatera MRD test to Japan’s PMDA for muscle-invasive bladder cancer.

$NTRAMedAI 8/10

Natera Stock Hits 52-Week High - Here's Why - Natera (NASDAQ:NTRA)

Natera (NTRA) reported Q2 adjusted loss of 47 cents per share, better than the 51-cent consensus. Revenue rose 37.7% to $752.8M, above $660.7M estimates, driven by higher test volumes and improved pricing. Oncology tests grew 56% YoY and the company processed 1.04M tests. Fiscal 2026 revenue guidance was raised to $2.85B-$2.91B. Analysts lifted price targets; shares hit a 52-week high.

$NTRAMedAI 8/10

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Natera (NTRA) shares hit fresh 52-week highs after Q2 revenue of $752.8M beat estimates of $661.3M and the company raised FY2026 revenue guidance to $2.85B-$2.91B. BTIG lifted its NTRA price target to $320 and JPMorgan to $360. Halozyme (HALO) also reached a 52-week high after Q2 revenue rose 48% to $481M; Leerink upgraded to Outperform and set $110.